Howard Capital Management Inc. Acquires 297 Shares of Moderna, Inc. (NASDAQ:MRNA)

Howard Capital Management Inc. boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,994 shares of the company’s stock after purchasing an additional 297 shares during the quarter. Howard Capital Management Inc.’s holdings in Moderna were worth $416,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. State Street Corp lifted its holdings in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after buying an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP raised its stake in Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the last quarter. Two Sigma Advisers LP bought a new stake in Moderna in the 3rd quarter valued at $23,825,000. International Assets Investment Management LLC boosted its holdings in Moderna by 10,687.1% in the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after purchasing an additional 316,552 shares during the period. Finally, Douglas Lane & Associates LLC grew its position in Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after purchasing an additional 298,715 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 2,664 shares of company stock worth $115,210 in the last three months. Insiders own 15.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on MRNA shares. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Berenberg Bank upped their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Finally, Evercore ISI set a $50.00 target price on Moderna in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $60.63.

Moderna Trading Down 4.6 %

NASDAQ MRNA opened at $33.90 on Tuesday. The firm has a market cap of $13.05 billion, a price-to-earnings ratio of -3.65 and a beta of 1.59. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The company has a 50 day moving average of $37.89 and a 200-day moving average of $52.10.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.